Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a single-site non-randomized open label pilot study. The investigators will use
accelerometer-based instrumented gait analysis and computerized cognitive testing to study
the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and
the effect of rivastigmine on motor and cognitive performance. All study participants will
tested for motor and cognitive performance at baseline (arm 1). A subgroup of study
participants will then be treated with rivastigmine for 12 weeks (arm 2), and the effect of
this treatment on gait measures and cognitive measures will be analyzed at the follow-up
visit 12 weeks after the baseline visit. Specifically, we will determine which components of
motor and cognitive impairment are associated with each other, and which components of the
two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore